Table 1.
Baseline characteristics of ProBP Trial and BHS participants
| Characteristics | ProBP Trial, Randomization Groups * | BHS (n=1261) | ||
|---|---|---|---|---|
| A (n=26) | B (n=28) | C (n=26) | ||
| Age, years | 43.6 (10.0) | 48.7 (10.6) | 50.4 (8.7) | 48.2 (5.3) |
| Female, n (%) | 8 (30.8) | 7 (25.0) | 10 (38.5) | 742 (58.8) |
| Black race, n (%) | 8 (30.8) | 8 (28.6) | 10 (38.5) | 434 (34.4) |
| Some college education, n (%) | 22 (84.6) | 26 (92.9) | 19 (73.1) | 640 (50.9) |
| Current smoking, n (%) | 2 (7.7) | 0 (0.0) | 3 (11.5) | 251 (19.9) |
| Current drinking, n (%) | 10 (38.5) | 11 (39.3) | 12 (46.2) | 700 (55.8) |
| Body mass index, kg/m2 | 29.1 (3.9) | 30.4 (5.0) | 28.4 (4.0) | 31.4 (7.8) |
| Physical activity, MET-hours per day | 12.0 (11.5) | |||
| Physical activity, 3 times/wk, % | 13 (50.0) | 15 (53.6) | 17 (65.4) | |
| Systolic blood pressure, mm Hg | 125.3 (8.9) | 126.6 (8.0) | 127.9 (9.9) | 123.3 (16.8) |
| Diastolic blood pressure, mm Hg | 81.0 (4.4) | 80.8 (5.1) | 82.2 (5.6) | 78.5 (11.3) |
| Hypertension, n (%) | 19 (70.1) | 15 (53.6) | 18 (69.2) | 785 (62.3) |
| Anti-hypertensive medication, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 439 (34.8) |
Values are mean (SD) or n (%). BHS indicates Bogalusa Heart Study; SD, standard deviation; MET, metabolic equivalent; and ProBP, Protein and Blood Pressure.
*
Sequence A received 40 g of soy protein for 8 weeks, then 40 g of milk protein for 8 weeks, and finally 40 g of complex carbohydrate for 8 weeks; those who were assigned to sequence B first received milk protein, then carbohydrate, and finally soy protein; and those who were assigned to sequence C first received carbohydrate, then soy protein, and finally milk protein.